Abstract Background Hypoxia-activated prodrug (HAP) is a promising candidate for highly tumor-specific chemotherapy. However. the oxygenation heterogeneity and dense extracellular matrix (ECM) of tumor. as well as the potential resistance to chemotherapy. https://pipingrockers.shop/product-category/energy-supplements/